Cloverleaf Bio Raises $33 Million Seed Financing To Advance RNA-Based Cancer Therapeutics
By Amit Chowdhry ● Sep 10, 2026
Cloverleaf Bio has closed an upsized and oversubscribed $33 million seed financing to advance its engineered transfer RNA, or tRNA, therapeutic platform and develop new treatments for cancer. The round was led by 4BIO Capital and included strategic investments from AbbVie Ventures, Eli Lilly and Company, and Boehringer Ingelheim Venture Fund, along with Draper Associates, Mission BioCapital and American Cancer Society BrightEdge.